

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Neurology</b>				
Alzheimer's disease (AD)	Retinoid X receptor (RXR)	<p>Mouse studies suggest agonizing RXR in the brain could help treat AD. In mouse models of AD, the oral small molecule RXR agonist Targretin bexarotene increased apolipoprotein E (APOE) expression, lowered hippocampal levels of soluble and insoluble toxic <math>\beta</math>-amyloid (A<math>\beta</math>) and decreased behavioral and cognitive deficits compared with vehicle control. ReXceptor Inc. will evaluate the safety of Targretin in a pilot trial in 12 healthy volunteers.</p> <p>Targretin is marketed by Eisai Co. Ltd. to treat cutaneous T cell lymphoma (CTCL).</p> <p><b>SciBX 5(9); doi:10.1038/scibx.2012.233</b>  <b>Published online March 1, 2012</b></p>	Use of Targretin to treat AD patented by Case Western Reserve University; exclusively licensed to ReXceptor	<p>Cramer, P.E. <i>et al. Science</i>; published online Feb. 9, 2012; doi:10.1126/science.1217697</p> <p><b>Contact:</b> Gary E. Landreth, Case Western Reserve University School of Medicine, Cleveland, Ohio            e-mail: <a href="mailto:gel2@case.edu">gel2@case.edu</a></p>